The complaint centers on claims that Insulet failed to maintain adequate internal controls, leading to significant risks of safety violations. According to the filing, the company downplayed the scope of a March 2026 medical device correction, asserting that the manufacturing issues impacted far more Pod products than public disclosures suggested. These allegedly false statements caused financial harm to shareholders once the full scale of the deficiencies became known.

Shareholders seeking to recover losses may contact attorneys Brian Schall and David Schwartz at the Los Angeles-based firm Schall Brown & Schwartz. While the class has not yet been certified, affected investors have until the end of August to explore options to serve as lead plaintiff or participate in potential recovery. The firm notes that no out-of-pocket fees are required for those joining the action, which alleges violations of the Securities Exchange Act of 1934.